- Home
- KBH vs TERN Comparison
KBH vs TERN Comparison
Compare KBH & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KBH | TERN |
|---|---|---|
| Founded | 1957 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.7B |
| IPO Year | 1987 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KBH | TERN |
|---|---|---|
| Price | $63.79 | $38.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 10 |
| Target Price | ★ $63.91 | $48.60 |
| AVG Volume (30 Days) | 1.2M | ★ 2.1M |
| Earning Date | 03-23-2026 | 03-19-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.15 | N/A |
| Revenue | ★ $6,236,214,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.74 | N/A |
| P/E Ratio | $10.32 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $48.90 | $1.87 |
| 52 Week High | $68.71 | $48.26 |
Technical Indicators
Market Signals| Indicator | KBH | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 63.53 | 57.46 |
| Support Level | $59.89 | $34.99 |
| Resistance Level | $62.84 | $39.50 |
| Average True Range (ATR) | 2.04 | 2.14 |
| MACD | 0.56 | 0.29 |
| Stochastic Oscillator | 98.38 | 82.37 |
Price Performance
Historical ComparisonAbout KBH KB Home
KB Home is an American construction company that focuses on residential construction in the United States. The company builds single-family homes and communities across different geographical segments which include the West Coast which also derives the majority of the revenue, Southwest, Central, and Southeast. The company operates in several markets and focuses on first-time and move-up homebuyers. It also invests in land acquisition and development to support future building activities and is also engaged in financial services operations which includes providing mortgage banking services through its joint venture with a third party.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.